Sangamo Therapeutics, Inc.
SGMONext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for SGMO. That does not mean none is planned.
Get an email about SGMO's next catalysts
Track Sangamo Therapeutics (SGMO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Sangamo Therapeutics, Inc. (formerly Sangamo Biosciences, Inc.) is an American biotechnology company based in Richmond, California, that develops cell and gene therapies for severe genetic diseases.
WebsitePlerixafor
Sickle Cell Disease
CERE-120: Adeno-Associated Virus Delivery of Neurturin
Idiopathic Parkinson's Disease
CERE-110: Adeno-Associated Virus injection Surgery
Alzheimer's Disease
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin)
Idiopathic Parkinson's Disease
TX200-TR101
Kidney Transplant Rejection
ST-920
Fabry Disease
SB-728-T
HIV
SB-509
Diabetes Mellitus, Type 1
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Plerixafor | Phase 2 | Sickle Cell Disease | - | - |
CERE-120: Adeno-Associated Virus Delivery of Neurturin | Phase 2 | Idiopathic Parkinson's Disease | - | - |
CERE-110: Adeno-Associated Virus injection Surgery | Phase 2 | Alzheimer's Disease | - | - |
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin) | Phase 2 | Idiopathic Parkinson's Disease | - | - |
TX200-TR101 | Phase 2 | Kidney Transplant Rejection | - | - |
ST-920 | Phase 2 | Fabry Disease | - | - |
SB-728-T | Phase 2 | HIV | - | - |
SB-509 | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Frequently asked questions
What is in Sangamo Therapeutics, Inc.'s drug pipeline?β
CatalystAlert tracks 8 drug candidates in Sangamo Therapeutics, Inc.'s (SGMO) pipeline across Phase 2. Its lead program is CERE-110: Adeno-Associated Virus injection Surgery (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sangamo Therapeutics, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Sangamo Therapeutics, Inc. (SGMO) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track SGMO biotech catalysts?β
Add SGMO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sangamo Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
